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Introduction and aims 
The cells of multicellular organisms communicate by extracellular signals. The 
communication between these cells involves the following cellular events: 1. the 
synthesis of the neurotransmitter or hormone; 2. its release; 3. the binding of this 
transmitter or hormone to its receptors on the surface of the target cell membrane; 4. 
the change of the cellular metabolism; and 5. the removal of the signal, which often 
results in cessation of the response of the cell. This thesis provides details on the key 
elements of this communication: the perception and the transduction of the signal, the 
heterogeneity of the receptors and their role in the transfer of the signal. On the 
surface or inside the cells, the membrane receptors are complex molecular units which 
are able to bind neurotransmitters, hormones and other substances. These receptors are 
responsible for two {unctions. Firstly, through their high-affinity, specific binding, 
they are able to recognize and distinguish biologically active ligands; secondly, 
through their interactions with their coupling proteins, they make it possible to 
mediate the apropriate signals, which finally leads to the response. In neurons, the 
realization and joining of these two functions into one process is called neuronal 
signal transduction. 
The muscarinergic (ml-m5), opioid (mu, delta, kappa, sigma, epsilon and 
lambda), and somatostatin receptors are transmembrane proteins. In the cell, when 
binding their high-affinity and selective agonists, they change their conformations and 
cause well-defined biochemical changes which can be inhibited by selective 
antagonists. These receptor types usually mediate well-characterized physiological 
functions and can be found in both the central and peripheral nervous systems and 
even in other non-neural tissues. They have a characteristic ontogenetic development, 
localization, and pharmacological and physiological features, with often a 
spectacularly demonstrable neuronal transport to the site of the physiological function. 
The number of neurotransmitter, neuromodulator and hormone receptors is currently 
known more than one hundred. For example, the receptor subtypes of the cholinergic 
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(muscarinergic M1-M5 and nicotinergic), opioidergic (mu, delta, kappa, sigma, 
epsilon and lambda), adrenergic (alfal, alfa2, betal and beta2), dopaminergic (D1 and 
D2) or serotoninergic (5HT,, 5HT1A, B, c , 5HT : and 5HT3) systems are well known 
and also well characterized on a pharmacological basis, and the primary structures 
(the nucleotide sequences) of some of their genes are already known. This thesis 
includes discussion of the heterogeneity of the muscarinergic and opioid receptors and 
presents relevant results. 
By the 1980s, the receptor hypothesis (relating to the conditions of binding of the 
ligand, the properties of the binding, and effects able to modulate the binding) and its 
common principles had been elaborated. The clarification of the conformational 
conditions of the receptor-ligand interaction started only afterwards, when the role of 
neuropeptides in signal transmission had been recognized. Several conformationally 
restricted peptide ligand are now known, and with their aid receptor-selective 
physiological effects can be produced. In many cases their application has made it 
possible to shed light on the role of the coupling proteins in signal transduction. 
The elements of the endogenous opioid system are to be found in both the central 
and peripheral nervous systems; they mediate a number of physiological effects. By 
means of immunology and molecular biology, localization of the endogenous ligands 
of the opioid system revealed the distribution of this system in the brain. Since the 
first publication of the binding properties and regional distribution of the opioid 
receptors, twenty years ago, our knowledge has increased rapidly. On the basis of the 
primary structure three, and on the basis of the pharmacology six receptor subtypes 
can be distinguished, among them the mu, delta and kappa, which are well 
characterized from molecular biological and pharmacological respects, while the 
epsilon, sigma and lambda receptor subtypes are only sketchily known and their 
physiological roles have not been elucidated. Although several pharmacological and 
physiological investigations involving the use of classical (non-peptide) opioid ligands 
suggested the existence of the main subtypes (mu, kappa and delta), the results of 
these early findings have now been re-evaluated following the accessibility and use of 
highly effective and selective ligands. 
With varying degrees of affinity, the endogenous opioid peptides (methionine-
enkephalin [ME], leucine-enkephalin [LE], dynorphin, etc.) are capable of binding to 
several opioid receptors, and so they might be responsible for biological functions 
mediated by different receptor types. For example, the delta opioid agonist [D-Ala : or 
D-Leu5]enkephalin is able to bind with a comparatively high affinity to the mu 
binding sites in the guinea-pig and rat brains. Obviously, for investigation of the 
physiological functions mediated by these opioid receptor subtypes, the need for 
highly selective ligands with high affinity and as resistant as possible to 
biodégradation is inevitable. 
The active conformation of the linear oligopeptides (e.g. ME or LE) can at most 
be revealed at the moment of interaction with the receptor. However, through the use 
of suitable structural modifications (e.g. methylation or cyclization of the peptide 
sceleton), even the conformational and electrical conditions of receptor-ligand 
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interactions can be clarified. In the instance of the enkephalins, the application of 
cyclic structures proved suitable. In solution, such analogues have only a small 
number of conformations and, if the sceleton is rigid enough, during binding to the 
receptor their conformation does not change. Such a conformationally restricted cyclic 
antagonist is D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP), with high affinity 
and mu selectivity. This analogue has a 32,500-times higher affinity for mu than for 
delta receptors, which practically means preclusion of the possibility of non-receptor-
specific responses. Our knowledge concerning the physiology, pharmacology, and 
localization of the opioid receptors is based almost exclusively on the application of 
receptor-selective and very often conformationally restricted opioid ligands. This 
thesis discusses the results of pioneering investigations in which such a delta or a mu 
opioid receptor-selective conformationally restricted ligand was used. 
The functions and features of any cell depend on the peptides inside the cell. 
However, the amounts of particular proteins are regulated by the function of the 
genes, i. e. the concentration of the mRNA coding the protein, the frequency of the 
translation and, of course, the stability of the protein. These three factors determine 
the scale and quality of the gene expression. The different activities of the genes and 
the control of the gene expression determine the functions and features of the cells. In 
eukaryotic cells, the control of the gene expression occurs decisively at the level of the 
transcription. The manifestations of the genes are determined by ontogenetic 
programmes, while the direction and the degree of any physiological process are 
determined by the unique process of gene expression. Some physiological or 
pathophysiological stimuli can increase the activity of certain genes and even the 
postranslational modifications of the primary transcripts can often be modified. 
In the cell, the synthesis, release and degradation of the transmitters or the 
hormones, and also the number of receptors are regulated, and as a result of the gene 
function they are under genetic control. The transmitter substances of certain 
transmitter systems (cholinergic, catecholaminergic, aminergic, etc.), e.g. the 
acetylcholine, are synthesized in several reaction steps involving collaboration with a 
number of enzymes; further, their degradation can occur, and thus the regulation of 
transmitter synthesis involves control of the gene expression of some (catabolic and 
anabolic) enzymes. However, the synthesis of transmitter substances in the 
neuropeptidergic systems is under direct genetic control (transcriptional control, 
posttranslational modifications), and thus the regulation of gene expression in these 
systems can be investigated directly. The genes of these peptides, as sensitive 
indicators, can rapidly react to homeostatic or pathophysiological changes, while their 
gene expressions can be regulated differently even in a single cell. This thesis 
discusses results concerning regulation of the synthesis of two neuropeptides, 
vasopressin (VP) and prodynorphin (PD), and also GSc coupling protein. In connection 
with the metabolic and homeostatic changes during signal transduction, an account is 
further given of experience regarding the regulation of some trace elements and some 
mono- and divalent cations at the level of the nervous system. 
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There are three known families of endogenous opioid peptides: 1. the 
proenkephalin A derivatives of which the most important are the ME and LE 
derivatives, and other longer fragments such as the hecta- and octapeptide fragments 
and peptide E; 2. PD (proenkephalin B) -derived peptides such as the dynorphin A and 
B fragments, a - and p-neo-endorphin and leumorphin; 3. the proopiomelanocortin 
(POMC) -derived peptides e.g. a - , (5- and y-endorphins. Although the nucleotide 
sequences of these genes are similar to a certain extent, their expressions differ, and 
several physiological and pathophysiological factors may be involved in their control. 
Beside its essential and well-characterized effects, VP seems important in 
memory processes and in the development of alcohol tolerance/dependence processes. 
The brain distribution of the cells expressing the peptide or rather the gene is well 
known; its localization in the brain has been revealed by immunocytochemistry and in 
situ hybridization studies. More and more details are available on the changes in VP 
level during altering environmental stimuli or experimental interventions, an also the 
regulation of its gene expression. Various factors are involved in this regulation. It 
was proved that, even in cells where PD and VP are colocalized, the regulations of 
their gene function differ considerably, even in the case of the same stimulus. The 
thesis discusses the changes in neuronal gene expression in the VP and PD genes 
during experimental intervention. 
In certain signal transduction systems, the perception of the extracellular stimulus 
and the generation of the intracellular response are carried out by the same peptide or 
peptide complex. In other cases, the relay and the intracellular effector are different 
proteins, which are coupled to an intermediate guanine nucleotide binding regulator 
protein (G protein). The G proteins have a heterotrimeric structure (a , p and y 
subunits); hardly a dozen Gsa subunits are known, but they are able to bind nearly a 
hundred receptors and ion channels defined by pharmacological and/or molecular 
biological methods. The primary structures, the localization and the role in signal 
transduction of the different G proteins are known, as are the changes in the regulation 
of their genes during physiological and pathophysiological stimuli. The thesis reports 
investigations by in situ hybridization and in vitro transcription methods of the 
changes in the Gsa expression during chronip ethanol treatment. 
There are a numerous methods suitable for the investigation of neuronal signal 
transduction. In investigations of the structure and the function of the receptors, use 
can be made of the registration of physiological, pharmacological (tissue or organ) and 
biochemical (receptor-induced activation of enzymes) responses or direct receptor-
binding measurements (membrane binding, autoradiography). Through the use of the 
high-affinity and often conformationally restricted, receptor-selective ligands 
developed in the last few years, the receptor-specific physiological responses can be 
determined, and the data acquired with the use of the early ligands, which often had 
cross-reactions, can frequently be re-evaluated. The use of these ligands with high 
specific activity made it possible to measure their binding to the receptors directly. 
With the aid of the methods of molecular biology (in situ hybridization, in vitro 
transcription, analysis of gene sequences, Northern analysis and polymerase chain 
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reaction), it is possible to investigate the control of the synthesis of certain peptides, 
including neuropeptides, at the level of the genes. 
This thesis investigates the signal transduction mediated by the different 
muscarinergic and neuropeptidergic (primarily opioidergic, somatostatinergic and 
vasopressinergic) receptors in neuronal tissue under normal, pathological or 
experimental conditions. Data acquired through the use of receptor-binding studies 
and the methods of molecular biology are summarized. An account is also given of the 
changes in the control of the gene functions of two neuropeptides (PD and VP) and a 
coupling protein (Gsa) during experimental interventions. 
In the course of the investigations, answers were sought to the following 
questions: 
1. What are the characteristics of the synthesis, the intracellular transport, the 
subcellular and autoradiographic distributions of the mAChRs in the central and 
peripheral nervous systems of the rat? 
2. How do the binding parameters of the mAChRs in the central and peripheral 
nervous systems of the rat change under physiological, pathophysiological and 
experimental conditions? 
3. How can the muscarinergic, somatostatinergic and delta opioid receptors be 
characterized in the course of the neurodegenerative Alzheimer's disease? Do these 
binding parameters change in two animal models of Alzheimer's disease? 
4. What are the characteristics of the heterogeneity of the mAChRs in the tissues 
of the heart and brain in the rat, and in human neuroblastoma cultures? 
5. What are the conditions of receptor selectivity according to the ligand 
conformations in the case of substance P and the delta and mu opioid receptors? 
6. What are the autoradiographic distributions of somatostatin, delta and mu 
opioid receptors in the central nervous system of the rat? 
7. What are the physiological and pharmacological characteristics of DPDPE and 
CTOP? 
8. How do the delta opioid receptors control the level of some neuronal trace 
elements which are mono- and divalent cations? 
9. How do the gene expressions of VP and PD alter during dehydration and 
chronic ethanol intoxication? 
Materials and methods 
Materials 
Studies were carried out with adult male and female rats of the CFY, Long-Evans, Wistar and Sprague-
Dawley strains, and with mice o f the C57BL/6NCR and CFLP strains, using several parts o f their central and 
peripheral nervous systems and hearts, the ileum o f guinea-pigs, the lumbar stretch of the spinal cords with 
the descending n. ischiadicus o f albino rabbits, the spinal cords of newborn pigs, the brains o f carps, 
postmortem human brain tissues from the parietal and frontal cortex and the hippocampus from normal 
members o f the British population (agc±S.E.M.=81±8years) and from subjects with Alzheimer's disease 
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(age±S.E.M.=78±6years) (Newcastle General Hospital, Newcastle upon Tyne. UK), bred cells o f the human 
neuroblastoma cell line (SH-SY5Y) which has a low passage (60-85). For the ontogenetic studies, the striatum 
and the cerebellum of rats from the same family but of different ages were used. 
Methods 
Anatomical methods: electron microscopy; enzyme histochemistry, autoradiography for light 
microscopical studies and histology. 
Surgical procedures: electrolytic lesion; nerve ligation; nerve transection; perineural suturing; isolated 
ileum preparation from guinea-pig; opening o f the spinal cord and the brain in order to apply substances (e .g. 
NVP, ibotenic acid, beta-BT and opioid substances); injection o f neurotoxins (ibotenic acid and bcta-BT) into 
the brain tissue or the ventricle in order to develop neurodegeneration; G A B A microinfusion through a 
capillary implanted into the superior cervical ganglion. 
Biochemical methods: subcellular fractionation; release of ACh by a solution with high K t 
concentration; receptor solubilization; cell culturing (SH-SY5Y); measurement of enzyme activity (ChAT. 
AChE and BuChE) and protein content; purified membrane preparation; receptor binding. 
The methods of molecular cell biology: in situ hybridization; in vitro transcription, nuclear run-on 
assay; Northern analysis (total RNA analysis); polymerase chain reaction; gene sequence analysis. 
Experimental interventions: acute opioid treatment; chronic morphine treatment; chronic aluminum 
intoxication; chronic ethanol intoxication; dehydration; chronic cold stress. 
Other methods: analgesia; measurement of body temperature and stereotype forms of motion. 
Physical-chemical methods: atomic absorption; gas chromatography; spectrophotometry. 
Mathematical methods: nonlinear regression analysis; image analysis (computer microdensitometry); 
statistics ( A N O V A , Dunnett or Sche f f epos t -hoc tests. Student's /-tests). 
Summary of new results and discussion 
1. In the striatum, the mAChRs are already synthesized intensively during early 
postnatal life. The early perikaryonal synthesis of the receptors and their rapid axonal 
transport are responsible for the fact that the development of the striatal mAChRs 
precedes the development of ChAT and AChE activities. In the striatum, the Bmax 
values increase in every subcellular fraction during ontogenesis, and the binding sites 
are highest in the microsomal and the synaptosomal fractions throughout. The number 
of mAChRs originating from areas outside the striatum is low. Consequently, in the 
subcellular fractions the measured receptor contents are due to the striatal pre- and 
postsynaptic receptors. 
The mAChR contents of two well-defined areas of the cerebellum, the archi- and 
paleocerebellum, were detected during postnatal development. The distributions of 
these receptors in the developing cerebellum are different: in the archicerebellum, the 
mAChR content is higher than in the paleocerebellum, and the rate of synthesis there 
is faster too. Our autoradiographic studies indicated that the molecular layer of the 
cerebellum exhibits higher [3H](-)QNB binding than the granular layer or the deep 
cerebellar nuclei. 
The mAChRs transported in the n. ischiadicus are synthesized in the motoneurons 
of the spinal cord and reach their presynaptic positions by rapid migration. Our results 
allowed the conclusion that the mAChRs undergo two-directional (anterograde and 
retrograde) transport in the nerves. The anterograde transport is extensive, whereas the 
retrograde transport moves a much lower content of the receptors. This seems to be 
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proved by our autoradiographic studies. The functional role of the presynaptic 
mAChRs could possibly be modulation of ACh release. During neurodegenerative 
processes, the number of receptors transported through the axon is in direct proportion 
to the time of axonal regeneration; 5 months after neural transection and resuturing, 
the bidirectional receptor transport, which returned to 23-26% of the control value, is 
able to provide a basis for the function of the regenerating nerve. 
2. The binding parameters of the mAChRs can be modified experimentally. We 
found that, as a result of in vivo beta-BT treatment, a nonselective, presynaptic 
neurodegeneration develops, which leads to decreases in both B,,^ and Kd. Repeated 
toxin treatment resulted in 52.2% of the control value in the case of B ^ , and 52.6% of 
* the control in the case of Kd. During cell death, the degraded receptor content 
presumably has a presynaptic localization; and its deficiency might be responsible for 
the changes in the binding parameters. The M2 character of the presynaptic mAChRs 
in the hippocampus is proved by the facts that AF-DX 116 stimulates and PZ has no 
effect on the release of ACh. 
During cold stress, the number of hippocampal receptors increases to 166.6% of 
the control value, while the Kj value does not change. This change in the receptor 
number is remarkable since it accompanies a protein content decrease of 21.5%. It 
was presumed that during chronic cold stress the adaptive biochemical changes 
(within them the decrease in ACh content or the release can give rise to the lack of the 
transmitter) cause functional denervations which, through homologous regulation, 
stimulate mAChR synthesis. 
Not all experimental interventions lead to changes in the binding parameters of 
the mAChRs. NVP, a specific inhibitor of ChAT, does not directly affect the mAChR 
content of the brain areas investigated. Although the ACh content decreases 
significantly in response to NVP and, can cause denervational hypersensitivity, during 
a short NVP treatment there is no significant de novo receptor synthesis. The long-
lasting inhibition produced by a chronically applied GABA microinfusion into the 
superior cervical ganglion (although free postsynaptic thickenings of the plasma 
membrane appear) does not give rise to significant changes in the receptor binding 
parameters. 
3. Binding studies on the muscarinergic radioligands ([3H](+)CD, [3H]PZ and 
[3H](-)QNB) suggest that there is no significant difference between the mAChR 
contents in human brain tissues of patients with Alzheimer's disease and controls, but 
the use of [5H]MCC to measure the binding of the nAChRs indicates a lower number 
in the disease. During our studies, we first reported the [3H]PZ binding in the human 
frontal cortex imaged by light microscopic autoradiography, which was compared 
with the [3H](-)QNB binding in consecutive sections. In the course of the disease, the 
number of somatostatin receptors decreases significantly, but there is no change in the 
number of delta opioid receptors. Selective lesioning of the nBM does not yield any 
changes either in the receptor number of the forebrain or the portion of the presumed 
individual receptor types. In the muscarinergic system as with other transmitter 
systems, we were not able to simulate faithfully all the neurochemical changes 
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observed in Alzheimer's disease by selective lesioning of the nBM. In the animal 
model in which an increased Al level characteristic of Alzheimer's disease was set up 
serious symptoms of cholinergic hypofunction were observed. In response to chronic 
AI intoxication, beside the increased endogenous Al content of the brain, significant 
decreases in ChAT activity and in the numbers of mAChRs and nAChRs were 
observed. 
4. During the direct and indirect receptor binding studies of selective and 
nonselective muscarinergic ligands prepared in rat brain and heart tissues, human 
neuroblastoma cell lines and carp brain, we described mAChR heterogeneity, in part 
confirming the previous findings, and in part providing new results on mAChR 
heterogeneity. Pharmacological verification of this receptor heterogeneity was greatly 
promoted by our investigations and data. We first described the direct binding 
properties of the new cardioselective antagonist, [3H]AF-DX 116 in brain and heart 
tissues and also in the human neuroblastoma SH-SY5Y cell line. 
5. Investigations of the neuropeptide systems, their receptors, their heterogeneity 
and the conformational requirements of their peptide ligands led to the development of 
a peptide antagonist with the greatest mu opioid receptor selectivity and affinity so 
far. D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH,, a cyclic somatostatin analogue 
octapeptide (CTOP), has more than 32,500-fold mu/delta selectivity, but practically 
no somatostatin activity. Investigations of the binding of [3H]CTOP to membranes or 
tissue slices reveals the receptor population indicated by this radioligand to be 
homogeneous; selective mu opioid ligands can inhibit it with high affinity, selective 
delta and kappa ligands have very low inhibitory activities, and non-opioid ligands fail 
to inhibit at all. On the other hand, the binding of [3H]DPDPE to membranes or tissue 
slices has high affinity towards delta receptors, and delta/mu selectivity. The specific 
binding can be inhibited with high affinity by using selective delta agonists or 
antagonists; CTOP and other mu selective ligands have low affinity to bind to these 
receptors. 
6. In acute and chronic experiments, the physiological effects of DPDPE and 
CTOP were investigated through the analgesia, withdrawal effects (e.g. hypothermia 
and loss of body weigh) or the ability to antagonize the effects. We established that 
CTOP, which according to the applied test has 10-400 times greater potencies as an 
antagonist than naloxone, inhibits the analgesic effects of morphine effectively, in a 
dose dependent manner, and produces withdrawal effects rapidly in morphine-
dependent animals. CTOP induces withdrawal hypothermia and loss in body weight in 
morphine-dependent animals. I.c.v. application of CTOP after development of a 
morphine-induced dependence decreases the body weight (by increasing salivation, 
urination and diarrhoea) in a dose dependent manner. This drug alone does not cause 
analgesia and does not have any effects on body weight or temperature. The fact that 
peripherally administered CTOP does not affect the symptoms of morphine-induced 
chronic dependence proves that the drug is virtually unable to cross the blood-brain 
barrier. This observation may be of great importance: in the development of the 
morphine dependence, the central and not the peripheral mu receptors play the key 
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role. We were among the first in the literature to publish the physiological effects of 
an opioid antagonist with high receptor selectivity. 
In parallel with the above studies in order to elucidate the actions realized 
through the delta receptors, we looked into certain physiological effects of DPDPE, 
which has a high delta opioid receptor selectivity. Dose-dependent analgesia 
antagonized by naloxone was observed in mice receiving i.c.v. DPDPE. Acute 
tolerance developed in response to the drug, and to a lesser degree physical 
dependence also appeared (withdrawal hypothermia and loss in body weight). DPDPE 
did not end the serious symptoms of morphine withdrawal. It was concluded from our 
experiments that the central delta opioid receptors play a role in the processes of 
analgesia. In a dose-dependent manner DPDPE also increased the stereotype 
scratching and scenting of rats. 
7. After characterizing [ ,25I]CGP 23,996, [3H]DPDPE, [3H]PL017 and [3H]CTOP 
binding to cryostat slides, we investigated the autoradiographic distribution of their 
specific binding in the rat brain. The distributions of the somatostatin, mu and delta 
receptors were examined with these conformationally restricted cyclic ligands by 
means of computer densitometry analysis. The autoradiographic characterization of 
the mu and delta opioid receptors with high selectivity and affinity was performed for 
the first time. 
8. We observed dose- and time-dependent effects (antagonized by naloxone) of 
the delta opioid receptor-selective agonist DPDPE in the levels of cations and trace 
elements in the rat brain. A subanalgetic dose of DPDPE transiently decreased in a 
time- and dose-dependent manner, the levels of Ca2*, Mg 2 \ Zn2* and Al3+ , but it did 
not influence the levels of Na*, K* and Mn"*. These effects of the drug on the ions can 
in all cases be inhibited by naloxone pretreatment. We observed that the high Al 
content developed by chronic Al intoxication, which also led to a cholinergic 
hypoftmction, can be decreased by DPDPE treatment. In the future, medical 
application through the delta opioid receptors could possibly decrease the endogenous 
Al content observed in Alzheimer's disease and probably in casual relation with it. 
9. During experimental interventions, we investigated the changes in the gene 
expression of the neuropeptide systems in the case of VP, PD and Gsa in the mouse 
brain. During dehydration, the VP gene expression increased in all examined 
hypothalamic and extrahypothalamic structures (except the n. suprachiasmaticus), and 
during chronic ethanol intoxication decreased in all areas. The PD gene expression 
also altered during these stimuli; it increased in the course of both experimental 
paradigms. In the areas where VP and PD can be colocalized (n. paraventricularis and 
n. supraopticus), these two genes produced different controls for the same stimuli, 
indicating that the nervous system reacts in a transmitter- and not stimulus-specific 
manner to the changed environment. In connection with this study, we first defined the 
partial sequence of the main, translating exon of the mouse PD gene, which also 
involves the mature hormones. During chronic ethanol intoxication, the expression of 
the Gsa gene altered, depending on the brain areas. 
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Possible applications of the results 
Our knowledge concerning the biochemical and receptor binding data on the 
mAChR types, which play an important role in the muscarinergic cholinergic 
transmission of the mammalian central and peripheral nervous systems, was quite 
defective, and thus the results reported in this thesis added further data to the previous 
studies, accordingly mostly having a basic research character. The realization that, in 
certain human diseases or as a result of some environmental stimuli, the binding 
parameters of the mAChRs could change, turned our attention to the importance of the 
receptors and the possibility of regulation by environmental factors through the 
receptors. The high-affinity and selectivity muscarinergic agonists and antagonists 
developed for the different receptor types may possible be suitable for the diagnosis or 
even cure of certain diseases. 
With our animal models (e.g. for Alzheimer's disease or paraplegia), we were 
able to simulate neuropathological alterations which are almost impossible to 
investigate in human subjects. Although the limits of these models are obvious, they 
still make it possible to perform several pharmacological, biochemical and molecular 
biological studies. 
The studies regarding the neuropeptidergic systems described in the thesis have 
already provided results exploitable in practice. Our studies concerning the 
neuropeptide receptors and the conformational requirements of their ligands resulted 
in the production of opioid ligands with high affinity and selectivity, and some of 
them can now be purchased commercially. The conformationally restricted, high-
affinity ligands with selectivity for a unique receptor and high resistance against 
biodégradation (we participated in their development and the first tests in biological 
systems) are much in demand for both basic and clinical research all over the world. 
These drugs lack the cross-reactivity often observed in the case of the opioid 
receptors, which was characteristic of the previously available opioid substances and 
consequently they have receptor specificity. In our other studies, e.g. on the role of the 
delta opioid receptors in the regulation of ion movement, we followed the control of 
the physiological processes based on this receptor heterogeneity. Using opioid ligands 
in our studies, we also provided the basis for clinical research in which the aim was 
the restoration of the neuronal trace element content or the ion surroundings damaged 
during an illness or a trauma. Investigations of the gene expressions of neuropeptide 
systems led to the first observations of basic research, e.g. partly sequencing the main 
exon of the PD gene coding the mature hormones, and we increased the knowledge 
concerning the function of the genes in respect of molecular biology, thereby turning 
attention to alcoholism and the results on the level of the gene function of the 
development of alcohol tolerance and dependcncc. 
